P
POC Pharma
Provides technology solutions for pharmacies and their stakeholders
About POC Pharma
PharmaPOC is a digital solutions provider that caters to the pharmaceutical industry, particularly in emerging markets. The company's primary goal is to help pharmaceutical stakeholders, including global leaders and domestic players, grow faster and more cost-effectively. They achieve this by offering software as a service (SaaS), data, and network solutions to digitalize their go-to-market models.
PharmaPOC's services are particularly beneficial for pharmaceutical companies, distributors, and wholesalers. The company's innovative approach to business is changing the way these entities interact with their customers, moving away from traditional face-to-face interactions and towards a more data-driven, digital approach, often referred to as "Phygital".
The company's unique offering includes measuring the impact of their clients' activities and providing a platform to elevate them to the next level. This is especially valuable for businesses managing large portfolios, such as a USD 7 billion portfolio that primarily makes sales in the retail channel. PharmaPOC's end-to-end digital solutions can provide a more efficient and impactful business model for these entities.
PharmaPOC operates in a market where pharmaceutical products need to be made widely accessible to patients. Their digital solutions not only help businesses grow but also ensure that patients have better access to necessary medications. The company generates revenue by offering their digital solutions and services to pharmaceutical stakeholders.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Kwun Tong District, Hong Kong
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 62.7/100
- Industry
- Health, Marketing
- Sub-industry
- BioTechnology, Health Platform, Ecommerce Solutions
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2022 | $10M | $41M | Alven · FJ Labs · Picus Capital · FEBE Ventures | ↗ |
| EARLY VCOther financing | Apr 2021 | $4.5M | $18M | 500 Global · FJ Labs · Picus Capital · Goat Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for POC Pharma is 1.2K monthly website visits, down 7.7% over the last three months. POC Pharma's team declined 11.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
500 Global
FJ Labs
Picus Capital- GCGoat Capital
FEBE Ventures
Alven
Other known investors2 additional known investors
AVV (Ascend Vietnam Ventures)
Enrico Pandian
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about POC Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See POC Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







